Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Temozolomide and Radiation in Glioblastoma
NCT01062399Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Dec 2010
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of everolimus in glioblastoma (GBM) (5 arms), sponsored by NRG Oncology. Primary endpoints: Dose-limiting Toxicity at 8 weeks and Progression-free Survival up to 36.7 months. Started Dec 2010; status: completed.
02
Drugs
everolimus
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01062399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01062399.